Affordable Access

Safe eradication of large established tumors using neovasculature-targeted tumor necrosis factor-based therapies

Authors
  • Huyghe, Leander
  • Van Parys, Alexander
  • Cauwels, Anje
  • Van Lint, Sandra
  • De Munter, Stijn
  • Bultinck, Jennyfer
  • Zabeau, Lennart
  • Hostens, Jeroen
  • Goethals, An
  • Vanderroost, Nele
  • Verhee, Annick
  • Uze, Gilles
  • Kley, Niko
  • Peelman, Frank
  • Vandekerckhove, Bart
  • Brouckaert, Peter
  • Tavernier, Jan
Publication Date
Jan 01, 2020
Source
Ghent University Institutional Archive
Keywords
Language
English
License
Green
External links

Abstract

Systemic toxicities have severely limited the clinical application of tumor necrosis factor (TNF) as an anticancer agent. Activity-on-Target cytokines (AcTakines) are a novel class of immunocytokines with improved therapeutic index. A TNF-based AcTakine targeted to CD13 enables selective activation of the tumor neovasculature without any detectable toxicity in vivo. Upregulation of adhesion markers supports enhanced T-cell infiltration leading to control or elimination of solid tumors by, respectively, CAR T cells or a combination therapy with CD8-targeted type I interferon AcTakine. Co-treatment with a CD13-targeted type II interferon AcTakine leads to very rapid destruction of the tumor neovasculature and complete regression of large, established tumors. As no tumor markers are needed, safe and efficacious elimination of a broad range of tumor types becomes feasible.

Report this publication

Statistics

Seen <100 times